(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 12.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.8%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Mannkind's revenue in 2025 is $301,736,000.On average, 4 Wall Street analysts forecast MNKD's revenue for 2025 to be $99,639,433,508, with the lowest MNKD revenue forecast at $97,049,802,361, and the highest MNKD revenue forecast at $102,388,615,390. On average, 4 Wall Street analysts forecast MNKD's revenue for 2026 to be $117,805,205,082, with the lowest MNKD revenue forecast at $106,015,326,309, and the highest MNKD revenue forecast at $137,336,362,746.
In 2027, MNKD is forecast to generate $130,516,489,344 in revenue, with the lowest revenue forecast at $126,216,903,886 and the highest revenue forecast at $137,078,626,945.